Positive and negative drug selection pressures on the N348I connection domain mutation: New insights from in vivo data

Antiviral Therapy

Volumn 15, Issue 2, 2010, Pages 203-211

  Price, Huw ^a   Asboe, David ^a   Pozniak, Anton ^a   Gazzard, Brian ^a   Fearnhill, Esther ^b   Pillay, Deenan ^c,d   Dunn, David ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; N348I PROTEIN; NEVIRAPINE; PROTEIN; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CASE CONTROL STUDY; CODON; CONTROLLED STUDY; DATA BASE; DRUG EFFECT; GENE MUTATION; HISTORY; IN VIVO STUDY; INTROSPECTION; LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; RISK;

ADENINE; ANTI-HIV AGENTS; BENZOXAZINES; CASE-CONTROL STUDIES; DATABASES, GENETIC; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LOGISTIC MODELS; MUTATION; NEVIRAPINE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 77950652922     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1511     Document Type: Article

References (29)

1. Kagan R, Winters M, Merigan T, Heseltine P. Expanded range of HIV-1 reverse transcriptase mutations detected through long range sequencing. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 629.
2. Cane PA, Green H, Fearnhill E, Dunn D, UK collaborative group on HIV Drug Resistance. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 2007; 21:447-455.
3. Ehteshami M, Beilhartz GL, Scarth BJ, et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 2008; 283:22222-22232.
4. Yap S, Radzio J, Sluis-Cremer N, Tachedjian G. Mechanism by which N348I in HIV-1 reverse transcriptase confers dual zidovudine/nevirapine resistance. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 79.
5. Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, et al. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci USA 2008; 105:10943-10948.
6. Yap SH, Sheen CW, Fahey J, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007; 4:e335.
7. Hachiya A, Kodama EN, Sarafianos SG, et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008; 82:3261-3270. (Pubitemid 351429905)
8. Gupta S, Fransen S, Paxinos EE, et al. Infrequent occurrence of mutations in the C-terminal regions of reverse transcriptase modulates susceptibility to RT inhibitors. XV International HIV Drug Resistance Workshop. 13-17 June 2006, Sitges, Spain. Abstract S143.
9. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido- 3′-deoxythymidine resistance. Proc Natl Acad Sci USA 2007; 104:317-322. (Pubitemid 46068029)
10. Radzio J, Yapp S-H, Harrigan R, Tachedjian G, SluisCremer N. N348I in HIV-1 reverse transcriptase counteracts the antagonism between thymidine analogue mutations and Y181C. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montréal, QC, Canada. Abstract 68.
11. Gotte M. Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing? PLoS Med 2007; 4:e346.
12. Biondi M, Beilhartz G, Götte M. N348I in the connection domain of HIV-1 reverse transcriptase exhibits differential effects on RNase H activity in response to NNRTI. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montréal, QC, Canada. Abstract 624.
13. UK Group on Transmitted HIV Drug Resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331:1368-1371.
14. UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-124.
15. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-125.
16. Dunn D, von Wyl V, Price H, Asboe D. The impact of the 0-0 cell on measures of amino acid covariation. AIDS 2010; 24:159-160.
17. Royston P, Parmar MK. Flexible parametric proportional hazards and proportional odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002; 21:2175-2197. (Pubitemid 34830755)
18. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-3800. (Pubitemid 41535530)
19. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1:43-46.
20. Geretti AM, Phillips AN, Kaye S, Booth C, Garcia A, Mackie N. Prevalence and patterns of antiretroviral drug resistance at low plasma HIV RNA load levels. Antivir Ther 2008; 13 Suppl 3:A156.
21. Nikolenko GN, Palmer S, Maldarelli F, et al. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA 2005; 102:2093-2098. (Pubitemid 40262017)
22. McCormick A, Burke A, Katundu P, et al. Prevalence and in vitro characteristics of reverse transcriptase N348I mutation in non-B subtypes, in the absence of viral load monitoring: the development of ART in Africa, nevirapine or abacavir substudy. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montréal, QC, Canada. Abstract 643.
23. Parikh UM, Barnas DC, Faruki H, Mellors JW. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 2006; 194:651-660. (Pubitemid 44297851)
24. Bohrer Lengruber R, Delviks-Frankenberry K, Nikolenko G, et al. Phenotypic role of HIV-1 reverse transcriptase C-terminal mutations and their relation with classical thymidine analogue mutations. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract WEPEA079.
25. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision). Geneva: World Health Organization 2006.
26. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44:128-143. (Pubitemid 44968997)
27. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000; 44:2475-2484. (Pubitemid 30650898)
28. Richman D, Shih CK, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A 1991; 88:11241-11245. (Pubitemid 21916016)
29. Paredes R, Bannister W, Cozzi-Lepri A, et al. Mutation A376S in the RT connection domain is associated with an increased risk of virological failure to nevirapine-based therapy in NNRTI-naive HIV-infected subjects: the EuroSIDA study. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montréal, QC, Canada. Abstract 646.